Search - tctmd.com

Displaying 1 - 20 of 37

Sort: Relevancy | Date

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Caitlin E. Cox

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

News Conference News TCT 2021

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

Yael L. Maxwell

October 15, 2021

Presentation TCT 2020

Effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned for primary percutaneous coronary intervention: The COMPARE CRUSH Trial

Presenter: George Vlachojannis

October 14, 2020

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Presenter: Armando P?rez de Prado

September 16, 2014

Presentation TCT 2014

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Presenter: Jos? Mar?a Cubero G?mez

September 16, 2014

Presentation TCT 2014

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Presenter: Stefan K. James, Cindy L. Grines, Tracy Y. Wang

September 15, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Presenter: E. Magnus Ohman

October 31, 2013

Advertisement

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

More DAPT Duration Data, More Calls to Tailor to Individual Patients

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

Effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned for primary percutaneous coronary intervention: The COMPARE CRUSH Trial

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content